Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

Chruściel, Elżbieta; Urban-Wójciuk, Zuzanna; Arcimowicz, Łukasz; Kurkowiak, Małgorzata; Kowalski, Jacek; Gliwiński, Mateusz; Marjański, Tomasz; Rzyman, Witold; Biernat, Wojciech; Dziadziuszko, Rafał; Montesano, Carla; Bernardini, Roberta; Marek-Trzonkowska, Natalia

doi:10.3390/cancers12030683

Cited by 35 publications

(22 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cells can be "reprogrammed" by means of modifications applied to either T-cells with antigen specific receptors (TCRs) or a genetic modification that induces expression of chimeric antigen receptors (CAR) of interest. While TCRs are natively expressed by T-cells and are MHC presentation dependent, CARs are artificially induced and can both recognise specific antigens as well as further activate T-cells-without the need for antigen presentation using MHC molecules [180]. MHC-1 are able to present intracellularly degraded peptides, while CARs are only designed to recognise specific cell surface antigens.…”

Section: Adoptive Cell Therapiesmentioning

confidence: 99%

The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

García-Sampedro

Gaggia

Ney

et al. 2021

JCM

View full text Add to dashboard Cite

Pancreatic cancer is a devastating disease with very poor prognosis. Currently, surgery followed by adjuvant chemotherapy represents the only curative option which, unfortunately, is only available for a small group of patients. The majority of pancreatic cancer cases are diagnosed at advanced or metastatic stage when surgical resection is not possible and treatment options are limited. Thus, novel and more effective therapeutic strategies are urgently needed. Molecular profiling together with targeted therapies against key hallmarks of pancreatic cancer appear as a promising approach that could overcome the limitations of conventional chemo- and radio-therapy. In this review, we focus on the latest personalised and multimodal targeted therapies currently undergoing phase II or III clinical trials. We discuss the most promising findings of agents targeting surface receptors, angiogenesis, DNA damage and cell cycle arrest, key signalling pathways, immunotherapies, and the tumour microenvironment.

show abstract

Section: Adoptive Cell Therapiesmentioning

confidence: 99%

The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

García-Sampedro

Gaggia

Ney

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…In this study, the therapeutic activity required the expression of perforin and CCL5 by adoptively-transferred T-cells [ 158 ]. T-cells can also be genetically modified to express a chimeric antigen receptor (CAR), encoding the tumor Ag-binding domain of an immunoglobulin linked to T-cell costimulatory molecules [ 159 ]. Preclinical studies, using humanized xenografted mouse models, assessed the activity of CAR T-cells against several human EOC Ags.…”

Section: Preclinical Investigations For the Development Of Effectimentioning

confidence: 99%

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer

Martinez

Delord

Ayyoub

et al. 2020

Cancers

View full text Add to dashboard Cite

In the past 20 years, the immune system has increasingly been recognized as a major player in tumor cell control, leading to considerable advances in cancer treatment. While promising with regards to melanoma, renal cancer and non-small cell lung cancer, immunotherapy provides, for the time being, limited success in other cancers, including ovarian cancer, potentially due to insufficient immunogenicity or to a particularly immunosuppressive microenvironment. In this review, we provide a global description of the immune context of ovarian cancer, in particular epithelial ovarian cancer (EOC). We describe the adaptive and innate components involved in the EOC immune response, including infiltrating tumor-specific T lymphocytes, B lymphocytes, and natural killer and myeloid cells. In addition, we highlight the rationale behind the use of EOC preclinical mouse models to assess resistance to immunotherapy, and we summarize the main preclinical studies that yielded anti-EOC immunotherapeutic strategies. Finally, we focus on major published or ongoing immunotherapy clinical trials concerning EOC.

show abstract

“…Adoptive T‐cell therapy is a highly individualized treatment, which requires the extraction of T lymphocytes from patients and their ex vivo activation to develop anti‐tumor immune cells that will mediate tumor regression. [ 108b,174 ] ACT also benefits from the host manipulation before cell transfer, which provides a better microenvironment and ultimately improves the anti‐tumor immunity. Adoptive T‐cell therapy uses either native host T lymphocytes that show anti‐tumor activity (TIL) or genetically‐modified native cells with anti‐tumor TCR or chimeric antigen receptors (CAR).…”

Section: Immune‐mediated Strategies To Regulate Tumor Immune Microenvmentioning

confidence: 99%

Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

Carreira

Acúrcio

Matos

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Melanoma is the most destructive and deadly among skin cancers. Patients presenting the most disseminated form of this disease have very low survival rates (≈15%) and highly restricted therapeutic alternatives. In recent years, the area of cancer immunotherapy has witnessed remarkable developments in the management of many cancers, including melanoma. In fact, immunotherapy unveiled as a feasible therapeutic alternative for late‐stage melanoma patients, specifically using immune checkpoint therapies. However, despite the exciting outcomes, only a small percentage of patients respond to these therapies, and severe immune‐related adverse reactions have been often reported. As such, most of preclinical and clinical studies currently explore melanoma tumor biology and immunology to guide the development of combinational immunotherapies aiming at relevant clinical efficacy and minimal toxicity. Herein, the current knowledge on melanoma biology and immunology is discussed, focusing on nanotechnology as a crucial strategy for the development of combinatorial approaches able to specifically modulate the function of key players responsible for melanoma evolution and evasion of host immune‐mediated attacks. Finally, the major challenges toward the clinical implementation of these emergent targeted nanomedicines for immunotherapy are further discussed, with particular focus on melanoma genomics, predictive biomarkers, clinical trial design, and clinical regulation of nanomedicines.

show abstract

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

Cited by 35 publications

References 227 publications

The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer

Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

Contact Info

Product

Resources

About